Are the side effects of baricitinib tablets serious? Clinical experience sharing

Baricitinib, also known as baricitinib, is an oral Janus kinase (JAK) inhibitor, which mainly inhibits JAK1 The span> and JAK2 signaling pathways intervene in the transmission of pro-inflammatory factors such as IL-6, IFN-γ, etc., thereby reducing the inflammatory response. The drug is approved in many countries and regions around the world for the treatment of moderate to severe rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), atopic dermatitis, and as an adjuvant treatment for severe patients with new coronavirus pneumonia (COVID-19). In actual clinical applications, the efficacy of baricitinib has been widely recognized, but it is also accompanied by a certain risk of side effects, especially in long-term use and in patients with multiple underlying diseases.

Judging from clinical studies and patient medication feedback, the common side effects of baricitinib are mainly concentrated in the immune system, infection risk, blood system and metabolic abnormalities. The more common adverse reactions include upper respiratory tract infection, nasopharyngitis, cough, nausea, headache and muscle soreness, etc., which generally occur in the early stage of medication, and most of them are mild to moderate and can be alleviated after appropriate dosage adjustment or symptomatic treatment. In addition, some patients experience increased blood lipids (such as increased total cholesterol and LDL-C), increased liver enzymes, or mild anemia, which are also common side effects. Liver and kidney function and blood lipid levels should be monitored during the initial treatment and during follow-up to ensure the safety of long-term medication.

However, special attention needs to be paid to the fact that baricitinib, as a type of immunosuppressant, not only suppresses excessive immunity, but also reduces the patient's defense against infection. Clinically, it has been observed that some patients develop herpes zoster, lung infection, urinary tract infection, etc. during treatment. Among them, older patients, patients with diabetes or renal insufficiency are at higher risk. In rare cases, serious infections (eg, sepsis, recurrence of tuberculosis) have been reported. Therefore, it is recommended to check potential sources of infection before treatment, including tuberculin test, hepatitis B virus test, etc.; during treatment, you should avoid contact with people with infectious diseases, and pay attention to symptoms such as fever, cough, and rash at all times.

Thrombotic events are also a type of risk that attracts clinical attention with baricitinib. According to drug safety updates issued by the FDA and EMA, long-term or high-risk patients have experienced venous thromboembolism (VTE) events, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Although the overall risk is not high, when combined with highBMIWhen using this drug in patients with a history of thrombosis or who have been bedridden for a long time, extreme caution should be exercised and the risk of thrombosis should be assessed before treatment. At the same time, patients are encouraged to drink more water, exercise appropriately, and avoid sitting for long periods of time to help prevent thrombosis.

In real-world clinical experience, many rheumatology immunologists said that baricitinib has a relatively stable effect in controlling rheumatoid inflammation indicators, relieving joint swelling and pain, and improving quality of life. Some patients have achieved a significant reduction in disease activity after 3 to 6 months of use. For some patients who have poor response to traditional DMARDs such as methotrexate (MTX), baricitinib can be used as an alternative or combined option. It is especially effective for moderate to severe patients with morning stiffness, severe joint swelling, rheumatoid factor (RF) or anti-CCP positivity. However, in order to minimize the risk of side effects, doctors generally make individualized dose adjustments based on the patient's weight, age, and complications. For example, starting from 4 mg per day, adjusting to 2 mg per day to maintain tolerance, or discontinuing the drug and changing the regimen due to adverse reactions.

It should be emphasized that patients should not stop taking baricitinib or increase the dose without authorization, and should strictly follow the doctor's instructions for monitoring and adjustment. Regular blood routine, liver and kidney function, blood lipids, electrolytes and infection-related indicators testing is an important prerequisite to ensure the safety of medication. If symptoms such as persistent fever, abnormal skin bleeding, severe fatigue, chest pain or shortness of breath occur during medication, you should seek medical evaluation immediately to eliminate the risk of serious complications.

In general, baricitinib is a JAK inhibitor with clear efficacy and advanced mechanism, which has played a positive therapeutic role in the field of rheumatism, immunity and other indications. However, its side effects cannot be ignored, especially in terms of infection risk, thrombophilia, metabolic abnormalities, etc., which still need to be carefully monitored. Clinicians need to conduct a comprehensive assessment of patients, select patients rationally, use medications scientifically, and conduct regular follow-up visits to maximize the efficacy and minimize adverse reactions. In the future, with the accumulation of real-world data and an in-depth understanding of the drug's mechanism of action, baricitinib's risk management program will be further improved to better serve clinical practice and patients.

Reference materials:https://www.drugs.com/